title: CyberKnife stereotactic irradiation for metastatic brain tumors.
abstract: BACKGROUND
  The CyberKnife provides a new technique for performing frameless stereotactic irradiation. So far, few reports have been published on clinical outcomes obtained with the CyberKnife. This report summarizes our clinical experience with CyberKnife irradiation for metastatic brain tumors.
  
  
  METHODS
  Seventy-seven lesions (48 patients) were evaluated and analyzed, and 66 lesions in 41 patients were treated with stereotactic radiosurgery (SRS). The prescribed dose was 9 to 30 Gy.
  
  
  RESULTS
  Freedom from progression of the tumors was more likely with a prescribed dose of at least 24 Gy than with one of less than 20 Gy (p=0.0244; log-rank test). The CR (complete response) rate was significantly higher when D99 was at least 24 Gy (p=0.0045). There were no severe side effects.
  
  
  CONCLUSIONS
  Stereotactic irradiation with the CyberKnife for metastatic brain tumors is effective and safe. D99 should be at least 24 Gy for CyberKnife SRS treatment.
authors.affiliation: Department of Multidisciplinary Radiotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
authors.forename: Shigetoshi
authors.initials: S
authors.lastname: Shimamoto
authors.forename: Takehiro
authors.initials: T
authors.lastname: Inoue
authors.forename: Hiroya
authors.initials: H
authors.lastname: Shiomi
authors.forename: Iori
authors.initials: I
authors.lastname: Sumida
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yamada
authors.forename: Eiichi
authors.initials: E
authors.lastname: Tanaka
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Inoue
mesh_terms: D001932:Brain Neoplasms / Q000556:secondary* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011829:Radiation Dosage; D016634:Radiosurgery; D012371:Robotics; D013997:Time Factors